TARSUS PHARMACEUTICALS, INC. Stock Issued During Period, Value, Issued for Services
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, issued for services for the quarter ending 2022-12-31 was $0.00.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, issued for services for the quarter ending 2022-09-30 was $0.00.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, issued for services for the quarter ending 2022-06-30 was $0.00.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, issued for services for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, issued for services for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, issued for services for fiscal 2021 was $5.49M, a 76.37% increase from fiscal 2020.
- TARSUS PHARMACEUTICALS, INC. stock issued during period, value, issued for services for fiscal 2020 was $3.12M.
| Period end | Stock Issued During Period, Value, Issued for Services 3 month | Stock Issued During Period, Value, Issued for Services 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $0.00 10-K · filed 2023-03-17 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-17 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $0.00 derived: sum of 4 quarters · filed 2023-03-17 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-11 | $0.00 derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $5.49M 10-K · filed 2023-03-17 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $8.61M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $11.72M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-03-31 | $5.49M 10-Q · filed 2022-11-09 | $11.72M derived: sum of 4 quarters · filed 2022-11-09 |
| 2020-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $3.12M 10-K · filed 2022-03-14 |
| 2020-09-30 | $3.12M 10-Q · filed 2020-11-25 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |